Episode 498: Do You Want a One and Done Cholesterol Infusion? The Long Road Ahead

0:00-31:14

Dr. Joel Kahn dives into a groundbreaking Phase 1 trial of Verve 102, a one-time intravenous gene-editing treatment that silences the PCSK9 gene to produce lasting LDL cholesterol reduction. Among 35 participants, the high-dose group saw LDL drop by 62% with mostly mild side effects — promising results, though Phase 2 and 3 trials and 15 years of follow-up still lie ahead. Also covered: updated colorectal cancer screening guidelines now starting at age 45, healthy lifestyle habits cutting mortality risk in cancer survivors by one-third, real-world weight regain data after stopping GLP-1 medications, why your B12 "normal" range may be too low, a blood test that may predict Alzheimer's years in advance, and a longevity preparedness tool from MIT AgeLab. Sponsored by Igennus — visit igennus.com/drkahn for 20% off.

Publisher

Heart Doc VIP with Dr. Joel Kahn

Link

heartdocvip.libsyn.com/episode-498-do-you-want-a-one-and-done-cholesterol-infusion-the-long-road-ahead

Published

June 2, 2026

Duration

31 min

Format

Podcast

Category

Lifestyle · Health & Wellness

Source

RSS feed

Host

Dr. Joel Kahn

HD

Heart Doc VIP with Dr. Joel Kahn

@heartdocvipwithdrjoelkahn

#cholesterolinfusion #roadahead #alternativehealth

The Nile